The strategic collaboration and license agreement is potentially worth more than USD 1 billion and offer patients less burdensome treatment regimens through sustained ocular delivery of therapies.

Through the exclusive option and license agreement, Novartis will fund Matchpoint’s research into oral covalent inhibitors and will have the option to exclusively develop and commercialize all products resulting from the collaboration.

The site in Ridgefield, N.J., will provide Thermo with additional U.S. drug product manufacturing capacity and will allow the company to meet the growing demand from pharma and biotech customers for U.S. drug product manufacturing.

Customers in Germany, France, Benelux, Poland, and the Nordics will be able to purchase the higher bulk density excipients, which are useful for those seeking to reduce tablet size, from Brenntag.

With this latest private transaction, Bain Capital, a private investment firm, joins PCI’s investor base of Kohlberg, Mubadala, and Partners Group, which are focused on supporting the company in its growth plans.

The partnership will see the integration of a real time glucose monitoring platform into a bioreactor range, eliminating the need for manual testing of nutrients and improving data resolution.

BioVersys and Shionogi are joining forces to progress the development of non-tuberculous mycobacteria clinical candidates with the potential for a selected number of molecules to be licensed for global commercialization.

The collaboration will leverage Bend’s expertise in controlled release formulation, manufacturing process, and analytical method development, and Starton’s deep understanding of continuous delivery of lenalidomide.

The companies will combine a drug discovery platform and a novel framework to reduce the cost and time it takes to develop complex therapies.

The proposed acquisition will expand Sanofi’s immunological portfolio with a precision medicine already approved for the treatment of ASM and ISM, a next-gen highly selective kinase inhibitor, and an investigational oral drug.

Porton Advanced has announced separate partnerships with TongEYE and Hualong Biological, as it moves into regenerative therapies for vision loss and innovative immunotherapies for solid tumors.

The court supervised purchase, which is still subject to relevant conditions, will see Regeneron acquire the assets of 23andMe, except for its Lemonaid Health business.

The acquisition of efimosfermin alfa, a Phase III-ready FGF21 analog targeting steatotic liver diseases, will expand GSK’s hepatology pipeline and establish a best-in-class therapy for MASH and ALD.

Through this sizable acquisition, Merck will accelerate its growth in the rare tumor segment and boost its U.S. oncology presence.

Pharmaceutical company, Granules India, has acquired Swiss CDMO, Senn Chemicals AG, for CHF 20 million (USD22 million) through its subsidiary, Granules Peptides as it enters the peptide therapeutics sector.

The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.

Drug delivery companies — SHL Medical and Kindeva Drug Delivery — have formed a partnership to enhance SHL Medical’s Molly® autoinjector platform aimed at pharmaceutical and biotechnology companies.

Advanced therapy medicinal products specialist CDMO, Porton Advanced, and clinical-stage biotech, Eureka Therapeutics, have entered a strategic collaboration to accelerate the development and commercialization of T-cell therapies for cancer treatment.

Curium, a global leader in nuclear medicine, has announced the acquisition of radiopharmaceutical company, Monrol, as the company aims to improve its position in the global nuclear medicine market,.

Novo Nordisk has entered into an exclusive global licensing agreement with Lexicon Pharmaceuticals for Lexicon’s promising drug candidate, LX9851, which targets gastrointestinal disorders.